T. Rowe Price Associates
HLVX

T. Rowe Price Associates’s HilleVax HLVX Stock Holding History

T. Rowe Price Associates’s Portfolio HLVX Stock Details HLVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,063
Closed -$15K – 3094
2025
Q1 		$15K Hold
10,063
– – ﹤0.01% 3017
2024
Q4 		$21K Hold
10,063
– – ﹤0.01% 2990
2024
Q3 		$18K Hold
10,063
– – ﹤0.01% 2994
2024
Q2 		$146K Buy
+10,063
New +$138K ﹤0.01% 2670
2022
Q3 		– Sell
-1,101,237
Closed -$12M – 2989
2022
Q2 		$12M Buy
+1,101,237
New +$13.1M ﹤0.01% 1291

Other funds holding HLVX

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
LMC
Lightspeed Management Company Menlo Park, California $988M AUM 7.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

T. Rowe Price Associates's HLVX Position: Q2 2025 in Review

T. Rowe Price Associates sold out of HilleVax (HLVX) in Q2 2025, closing a stake of 10,063 shares — an estimated $15K sold.

T. Rowe Price Associates first reported a position in HLVX in Q2 2022 and held it in 5 quarters. The position peaked at $12M in Q2 2022. 74 funds tracked by Wall St. Rank hold HLVX as of Q2 2025.

  • T. Rowe Price Associates reported no remaining HilleVax position as of Q2 2025 after selling out during the quarter.
  • T. Rowe Price Associates sold 10,063 HilleVax shares in Q2 2025, an estimated $15K.
  • T. Rowe Price Associates first reported a position in HilleVax in Q2 2022 and held it in 5 quarters.
  • T. Rowe Price Associates's HilleVax position peaked at $12M in Q2 2022.
  • 74 funds tracked by Wall St. Rank held HilleVax as of Q2 2025.

Based on T. Rowe Price Associates's 13F filing for Q2 2025, filed 14 Aug 2025.